A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

• Status: Not yet recruiting
• Trial end date: 2024-10-01

Summary

The purpose of this study is to test the safety and efficacy of the study drug daratumumab, when given together with Pomalidomide, Dexamethasone, and All-Transretinoic Acid (ATRA).

• Phase: Phase 2

Details

• Lead Sponsor: Hackensack Meridian Health
• Collaborator: Janssen, LP
• Treatments: Daratumumab; Dexamethasone; Pomalidomide; Tretinoin